What question did this study set out to answer?

March 1, 1994Phlebology The Journal of Venous Disease

Role of Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thromboembolism after Surgery

View Full Paper

Ask AI

Bookmark

Why the study?

Do low molecular weight heparins reduce the incidence of DVT and PE in patients undergoing surgery compared to placebo, dextran, or unfractionated heparin?

Population

Patients undergoing surgery (specifically high-risk orthopaedic and general surgery)

Comparison

Low molecular weight heparins (LMWHs) vs Placebo, dextran, or unfractionated heparin

Design

Systematic_review

Authors

SAShahriyour AndazBronx-Lebanon Hospital Center DSD. A. ShieldsRoyal College of Surgeons in Ireland JSJ H ScurrUniversity College Hospital

Discussion

Member takes

Implication

LMWH prophylaxis should be prioritized in high-risk orthopaedic surgery; confirms DVT reduction versus comparators but leaves open superiority over UFH in general surgery.

Key Points

To examine the effectiveness and safety of low molecular weight heparins in the prevention and treatment of deep venous thrombosis and pulmonary embolism after surgery.
Reviewed published randomized controlled trials from Medline (since 1984) and journal reference lists comparing low molecular weight heparins with placebo, dextran, or unfractionated heparin.
Assessed outcomes including deep venous thrombosis confirmed by isotope scanning or venography, pulmonary embolism, and bleeding complications.
Low molecular weight heparin significantly reduced deep venous thrombosis incidence compared to placebo, dextran, and unfractionated heparin in high-risk orthopedic surgical patients, though superiority over unfractionated heparin was inconclusive in general surgery.
Data regarding pulmonary embolism reduction with low molecular weight heparins versus dextran or unfractionated heparin remained inconclusive.
Safety profiles showed low molecular weight heparins were at least as safe as unfractionated heparin regarding major hemorrhage and postoperative blood loss.

Structured PICO

Do low molecular weight heparins reduce the incidence of DVT and PE in patients undergoing surgery compared to placebo, dextran, or unfractionated heparin?

Population

Patients undergoing surgery (specifically high-risk orthopaedic and general surgery)

Intervention

Low molecular weight heparins (LMWHs)

Comparator

Placebo, dextran, or unfractionated heparin

Outcome

Incidence of deep venous thrombosis (DVT) as assessed by isotope scanning and/or venography, and the incidence of pulmonary embolism (PE) and bleeding complicationshard clinical

LMWHs are effective for thromboprophylaxis in high-risk orthopaedic surgery patients, but evidence is inconclusive for their superiority over unfractionated heparin in general surgery.

Cite This Study

Andaz et al. (1994) studied this question.

synapsesocial.com/papers/6a852028dc9e7acb57f23e49 https://doi.org/10.1177/026835559400900102

View Full Paper

Ask AI

Bookmark

Implication

LMWH prophylaxis should be prioritized in high-risk orthopaedic surgery; confirms DVT reduction versus comparators but leaves open superiority over UFH in general surgery.

Role of Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thromboembolism after Surgery

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Role of Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thromboembolism after Surgery

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider